-

Eurofins CDMO Alphora Inc. Announces the Launch of Expanded Drug Product Analytical Laboratory

MISSISSAUGA, Canada--(BUSINESS WIRE)--Eurofins CDMO Alphora Inc., a global Contract Development & Manufacturing Organization and part of the international network of Eurofins laboratories, is pleased to announce a significant expansion of its Drug Product Analytical Services Laboratory, increasing its footprint three-fold. Located in Mississauga, Canada, the expanded facility marks the addition of specialized equipment and analytical techniques, tailored to offer comprehensive analytical support for drug product programs. The laboratory has expanded to encompass water activity measurements, intrinsic dissolution studies, additional glove box systems, an added suite of HPLCs, new stability chambers and gas chromatography.

Eurofins CDMO Alphora Inc is committed to supporting the development and manufacturing of life-saving therapies and providing the highest standards of quality, customized support, and expert analysis to its clients. Through the Drug Product Analytical Services Laboratory expansion and Eurofins CDMO Alphora Inc’s drug product capabilities and extensive suite of Solid-State Research and Development, Eurofins CDMO Alphora is well positioned to support even the most challenging drug development programs.

To learn more, please visit:
https://www.eurofins.com/biopharma-services/cdmo/services/small-molecules-dp-development-manufacturing/

About Eurofins CDMO Alphora Inc.
Eurofins CDMO is a leading global Contract Development and Manufacturing Organization that provides clients with active pharmaceutical ingredients (“API’s”) / drug substance and drug product development for small molecules, biologics and phytocannabinoids via synthetic route. Its service offering encompasses drug substance/API development, solid state research and development, pre-formulation, formulation and development, analytical development, Non-GMP & GMP manufacturing, upstream development, downstream development, ADC Conjugation. Operating with facilities in Europe, North America and India, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With ca. 62,000 staff across a network of more than 900 laboratories in over 1,000 companies in 62 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.

Contacts

For further information:
Cheryl Young
Senior Vice President Business Operations
Eurofins CDMO Alphora Inc.
Cheryl.Young@bpt.eurofinsca.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

For further information:
Cheryl Young
Senior Vice President Business Operations
Eurofins CDMO Alphora Inc.
Cheryl.Young@bpt.eurofinsca.com

More News From Eurofins

Eurofins MET Laboratories Opens New Safety, EMC, Wireless, and Renewable Energy Laboratory in the Boston Tech Corridor

BOSTON--(BUSINESS WIRE)--Eurofins MET Laboratories, part of the Eurofins Electrical & Electronics global network, announces the opening of its new state-of-the-art 60,000-square-foot testing laboratory in Littleton, Massachusetts – a prime location in the Boston innovation corridor. Positioned at the epicenter of New England's med-tech, wireless innovation, clean energy, and advanced electronics ecosystem, the capabilities of this laboratory further position Eurofins MET Laboratories as the...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 26th January to 30th January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 26/01/2026 FR0014000MR3 5 000 70.7336 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 27/01/2026 FR0014000MR3 5 000 70.9680 XPAR EUROFINS SCIENTIFIC 529900JEHFM47...

Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth, Accelerating Organic Revenue Growth, Margin Expansion, and Higher Free Cash Flow and Confirms Its 2027 Objectives

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited consolidated financial results for the year ending 31 December 2025, as described in the first paragraphA of the Business Review section of this press release. Financial highlights in FY 2025 Basic EPS8 grew 24% to €2.31 in 2025 vs €1.87 in 2024, driven by a strong operating performance and starting to reap the benefits from Eurofins five-year investment programme in its hub and spok...
Back to Newsroom